ClinicalTrials.gg
Active, not recruitingNCT07678983Updated Jul 14, 2026

Whole-Body Vibration in Parkinson Disease

An interventional study of Functional Exercise Based Physiotherapy and Low-Frequency Whole-Body Vibration Therapy in Parkinson's Disease, Balance and Gait, sponsored by Izmir Bakircay University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Izmir Bakircay University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Enrollment
12th of 99
66 · median 32
Started
2026
with 28 others
No phase
92 of 172
26 open now
Primary completion
2026-12
later than 37 of 55 live
Registered
161st of 172
by date

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 12th largest by enrollment of the 99 interventional ones that give a count, is one of 29 that started in 2026, is one of 92 with no phase, reaches primary completion later than 37 of the 55 other live ones, and was the 161st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effects of different frequencies of Whole Body Vibration (WBV) application on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson's disease.

Study Hypotheses:

H0.1 - There is no effect of different frequencies of WBV application on balance performance in patients with Parkinson's disease.

H1.1 - There is an effect of different frequencies of WBV application on balance performance in patients with Parkinson's disease.

H0.2 - There is no effect of different frequencies of WBV application on gait performance in patients with Parkinson's disease.

H1.2 - There is an effect of different frequencies of WBV application on gait performance in patients with Parkinson's disease.

H0.3 - There is no effect of different frequencies of WBV application on cognitive functions in patients with Parkinson's disease.

H1.3 - There is an effect of different frequencies of WBV application on cognitive functions in patients with Parkinson's disease.

H0.4 - There is no effect of different frequencies of WBV application on dual-task performance in patients with Parkinson's disease.

H1.4 - There is an effect of different frequencies of WBV application on dual-task performance in patients with Parkinson's disease.

H0.5 - There is no effect of different frequencies of WBV application on reaction time in patients with Parkinson's disease.

H1.5 - There is an effect of different frequencies of WBV application on reaction time in patients with Parkinson's disease.

H0.6 - There is no significant difference between medium-frequency and low-frequency WBV in terms of balance performance in patients with Parkinson's disease.

H1.6 - There is a significant difference between medium-frequency and low-frequency WBV in terms of balance performance in patients with Parkinson's disease.

H0.7 - There is no significant difference between medium-frequency and low-frequency WBV in terms of gait performance in patients with Parkinson's disease.

H1.7 - There is a significant difference between medium-frequency and low-frequency WBV in terms of gait performance in patients with Parkinson's disease.

H0.8 - There is no significant difference between medium-frequency and low-frequency WBV in terms of cognitive functions in patients with Parkinson's disease.

H1.8 - There is a significant difference between medium-frequency and low-frequency WBV in terms of cognitive functions in patients with Parkinson's disease.

H0.9 - There is no significant difference between medium-frequency and low-frequency WBV in terms of dual-task performance in patients with Parkinson's disease.

H1.9 - There is a significant difference between medium-frequency and low-frequency WBV in terms of dual-task performance in patients with Parkinson's disease.

H0.10 - There is no significant difference between medium-frequency and low-frequency WBV in terms of reaction time in patients with Parkinson's disease.

H1.10 - There is a significant difference between medium-frequency and low-frequency WBV in terms of reaction time in patients with Parkinson's disease.

Read the detailed description

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and affects approximately 10 million people worldwide. Each year, more than 60,000 new cases are diagnosed in the United States alone, and this number is reported to be increasing globally. With the aging population, the prevalence of Parkinson's disease is also rising; in particular, it is reported that the prevalence among individuals over 65 years of age ranges between 1 and 2 per 1,000 people. Therefore, Parkinson's disease represents a significant health and social care burden at both individual and societal levels.

Recent studies emphasize that Parkinson's disease is a multidimensional condition and that the changes occurring during its course play a key role in disease progression.

Balance impairment and postural control deficits are among the most common problems in Parkinson's disease. Research has shown that the risk of falls is significantly increased in this patient group, with approximately 60% of patients exhibiting a tendency to fall. Balance disorders not only threaten physical safety but also restrict individuals' independence and participation in activities of daily living. Therefore, balance is considered one of the primary targets for improvement in Parkinson's rehabilitation.

Gait disturbances are another prominent functional limitation in Parkinson's disease. Reduced walking speed, shortened step length, and irregular gait rhythm lead to significant limitations in daily living activities. Loss of gait performance reduces mobility and makes independent living more difficult. For this reason, gait is considered one of the most critical targets in physiotherapy and rehabilitation programs.

Cognitive impairments are also commonly observed in patients with Parkinson's disease. These impairments typically occur in the domains of attention, executive functions, and memory. Cognitive deficits reduce independence in daily activities, limit social participation, and decrease quality of life. In addition, cognitive impairments may negatively affect the sustainability of gains achieved through motor rehabilitation.

One of the important challenges faced by Parkinson's patients is impaired dual-task performance. In daily life, individuals often need to perform both motor and cognitive tasks simultaneously. However, in Parkinson's disease, significant performance declines are observed in such tasks due to attention deficits, executive dysfunction, and motor control problems. Impairments in dual-task performance represent a critical area where cognitive and motor limitations intersect.

Another important parameter in Parkinson's disease is prolonged reaction time. It is one of the prominent effects of the disease on motor and cognitive functions. Delayed motor responses to sensory stimuli lead to reduced performance in situations requiring quick decision-making and rapid movements in daily life. Prolonged reaction times increase the risk of falls and negatively affect balance and gait performance during dual-task activities. Therefore, reaction time is considered an important functional parameter that should be assessed and improved in Parkinson's rehabilitation programs.

In recent years, Whole Body Vibration (WBV) has attracted attention in studies on non-invasive physical interventions in patients with Parkinson's disease. WBV enhances proprioceptive feedback by stimulating muscle contractions through mechanical vibration, thereby contributing to improvements in motor performance and postural control. This stimulation activates spinal reflexes, supporting rapid and coordinated muscle contractions, and also helps regulate muscle tone and postural control. In addition, WBV increases neuronal activity in cortical motor areas, strengthens neuromuscular coordination, and supports motor learning processes.

Studies have reported that WBV has positive effects on balance, postural control, and gait. However, the literature regarding its effects on cognitive functions and dual task performance remains limited. Most existing studies have been conducted with small sample sizes; there is heterogeneity in intervention protocols in terms of frequency, duration, and number of sessions, and frequencies have not been comparatively examined. Furthermore, there are no studies evaluating cognitive parameters and dual task performance in this context, which limits the generalizability of the findings. These gaps highlight the need for studies investigating the frequency dependent effects of WBV on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson's disease.

The aim of study is to evaluate the effects of different frequencies of WBV on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson's disease.

This study is the first to comparatively examine the frequency-dependent effects of WBV on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson's disease. The findings are expected to contribute to the development of physiotherapy and rehabilitation models tailored to Parkinson's patients, focusing on targeted outcomes and individualized needs by considering the frequency dependent effects of WBV.

Study was designed as a randomized controlled, single-blind trial. In accordance with this aim, all assessments and interventions will be conducted at the Izmir Bakırçay University Physiotherapy and Rehabilitation Practice and Research Center. Patients diagnosed with Parkinson's disease who have been followed up or are currently being followed at the Neurology Department of Çiğli Training and Research Hospital, Izmir Bakırçay University, and who are referred to the Izmir Bakırçay University Physiotherapy and Rehabilitation Practice and Research Center, and who meet the inclusion and exclusion criteria, will be included in the study. Written informed consent will be obtained from all participants prior to enrollment.

In the study, participants' demographic and clinical characteristics, balance, gait, cognitive functions, dual task performance, and reaction time will be assessed using standardized evaluation tools. Demographic and clinical data will be collected using a structured assessment form and will include age, sex, height, weight, body mass index, educational status, marital status, smoking and alcohol use, medical history, and Parkinson's disease related clinical characteristics (Onset Date, Disease Duration, and Disease Stage), as well as Unified Parkinson's Disease Rating Scale (UPDRS) scores and comorbidity information. Comorbidity status will be evaluated using the Charlson Comorbidity Index. Balance will be assessed using the Mini Balance Evaluation Systems Test (Mini-BESTest), while gait performance will be measured using the 10 Meter Walk Test. Cognitive functions will be evaluated using the Verbal Fluency Test, Digit Span Test, Trail Making Test, and Stroop Color and Word Test. Dual-task performance will be assessed using the Dual Task Walking Test and the Dual-Task Timed Up and Go Test, and reaction time will be measured using the Ruler Drop Test. All assessments will be conducted according to standardized protocols, and all data will be recorded systematically.

Participants will be allocated to the intervention and control groups using a stratified randomization method to ensure that the three groups are homogeneous in terms of demographic and clinical characteristics. The intervention group will then be further randomly divided into two subgroups according to the applied frequency levels: Low Frequency (3-10 Hz) and Medium Frequency (12-20 Hz). In both groups, the interventions will be conducted for a total of 8 weeks, two days per week, in a hospital setting under appropriate safety conditions. Participants in the intervention group will perform the same functional exercise based physiotherapy program as the control group, with equal duration and intensity. In addition to the control intervention, the intervention group will receive a 20 minute Whole Body Vibration (WBV) application, which will be integrated at different frequencies (Low or Medium) depending on the assigned subgroup.

03

Conditions studied

  • Parkinson's Disease
  • Balance
  • Gait
  • Cognitive Function
  • Dual-Task Performance
  • Reaction Time

Browse trials for

Keywords

  • Parkinson's Disease
  • Whole Body Vibration (WBV)
  • Balance
  • Gait
  • Cognitive Function
  • Dual-Task Performance
  • Reaction Time
  • Postural Control
  • Rehabilitation
  • Neuromuscular Coordination
  • Neurology
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 30-80 years with a clinical diagnosis of Parkinson's disease. Hoehn and Yahr stages 1-3.
  • Stable medical treatment (no changes in medication for the past 4 weeks).
  • Willingness to participate and provision of written .
  • Score of 24 or higher on the Standardized (SMMSE).

Exclusion criteria

Exclusion Criteria

  • Advanced stage Parkinson's disease (Hoehn and Yahr stage >3) or presence of severe motor complications.
  • History of surgical interventions or other neurological/vestibular disorders that may affect balance and gait (E.G., stroke, epilepsy, peripheral neuropathy).
  • Presence of severe cardiovascular or respiratory conditions that may affect stability (E.G., heart failure, uncontrolled hypertension, advanced ).
  • Conditions contraindicating whole-body vibration (WBV) application (E.G., severe osteoporosis, active thrombosis).
  • Psychiatric disorders or major depression that may interfere with treatment participation.
  • Significant communication or language impairments affecting participation.

Withdrawal Criteria

  • Voluntary withdrawal from the study.
  • Development of health problems during the intervention that prevent completion of the study (E.G., unexpected acute illness or temporary medical condition).
  • Changes in medication or medical status during the study that may affect participation or performance.
  • Non-adherence to the protocol (attendance rate below 80% of sessions).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Control Group

    Participants, will receive a functional exercise based physiotherapy program in a hospital setting. The program will be supervised and conducted twice per week for 8 weeks.

    Behavioral: Functional Exercise Based Physiotherapy

  • Experimental
    Low Frequency Whole Body Vibration (WBV) Group

    Participants will receive a functional exercise based physiotherapy program in a hospital setting, conducted twice per week for 8 weeks. In addition, Whole Body Vibration (WBV) will be applied for 20 minutes per session at a low frequency range (3-10 Hz).

    Behavioral: Functional Exercise Based Physiotherapy · Device: Low-Frequency Whole-Body Vibration Therapy

  • Experimental
    Medium Frequency Whole Body Vibration (WBV) Group

    Participants will receive a functional exercise based physiotherapy program in a hospital setting, conducted twice per week for 8 weeks. In addition, Whole Body Vibration (WBV) will be applied for 20 minutes per session at a medium frequency range (12-20 Hz).

    Behavioral: Functional Exercise Based Physiotherapy · Device: Medium-Frequency Whole-Body Vibration Therapy

Interventions

  • BehavioralFunctional Exercise Based Physiotherapy

    A supervised functional exercise-based physiotherapy program will be conducted in a hospital setting twice per week for 8 weeks.

  • DeviceLow-Frequency Whole-Body Vibration Therapy

    Whole-Body Vibration (WBV) will be applied as an adjunct to the functional exercise-based physiotherapy program. The intervention will be conducted in a hospital setting twice weekly for 8 weeks, with each session lasting 20 minutes. WBV will be applied to the low-frequency group at a frequency range of 3-10 Hz.

  • DeviceMedium-Frequency Whole-Body Vibration Therapy

    Whole-Body Vibration (WBV) will be applied as an adjunct to the functional exercise-based physiotherapy program. The intervention will be conducted in a hospital setting twice weekly for 8 weeks, with each session lasting 20 minutes. WBV will be applied to the medium-frequency group at a frequency range of 12-20 Hz.

06

What researchers measure

Primary outcomes

  1. Mini Balance Evaluation Systems Test (Mini-BESTest)

    Participants will be assessed while standing on a flat and firm surface. During the test, appropriate safety precautions will be taken if necessary to ensure participant safety. The assessment includes 4 subcomponents and 14 items: anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. Each subcomponent represents different aspects of balance control and evaluates specific components of the postural control system. In each section of the assessment, participants will be asked to perform various functional tasks, and their performance will be observed during these tasks. The tasks include sit-to-stand and stand-to-sit transitions, standing balance, forward reach, backward stepping, standing with eyes closed, and turning while walking. Each item is scored on a 0-2 scale (0 = Severe İmpairment, 1 = Moderate İmpairment, 2 = Normal/No İmpairment), with a total score ranging from 0 to 28.

    Time frame: Baseline and 8 weeks

  2. 10 Meter Walk Test (10MWT)

    Participants will be assessed while standing on a flat, firm, and non-slip surface. Participants will be asked to walk a 14 meter walkway, with the central 10 meter section used for timing. Walking speed will be recorded over this 10 meter distance. The test will be performed under two conditions: comfortable walking speed and maximum walking speed, with two trials for each condition. Completion time will be measured using a stopwatch, and walking speed will be calculated and expressed as meters per second (m/s) based on the average of the trials.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Verbal Fluency Test

    The test will be administered in two conditions: Semantic (Category) Fluency and Phonemic (Letter) Fluency. In the semantic fluency task, participants will be asked to generate as many words as possible belonging to a specific category (E.g., "Animals") within a given time period. In the phonemic fluency task, participants will be asked to produce as many words as possible beginning with a specific letter (E.g., "K") within a given time period. Each correct word that meets the criteria will be scored as 1 point. Repetitions, proper nouns, and responses that do not meet the specified criteria will be excluded from the scoring.

    Time frame: Baseline and 8 weeks

  2. Forward-Backward Digit Span Test

    Participants will be presented with sequences of numbers with increasing length and will be asked to repeat them in the correct order (Forward) and in reverse order (Backward). In both sections, the number sequences will progressively increase in length (E.G., starting with 3 digits, then 4 digits, then 5 digits, etc.). If the participant makes an error, the trial will be terminated or the sequence length will be recorded as a failure for that level. Scoring will be based on the correctly reproduced digit sequences in forward and backward conditions or the longest correctly recalled sequence. Each correct response will be scored as 1 point, and both correct and incorrect responses will be recorded.

    Time frame: Baseline and 8 weeks

  3. Trail Making Test (TMT)

    The test will be administered in two parts: Part A and Part B. In Part A, participants will be asked to connect numbers from 1 to 25 in ascending order as quickly as possible. In Part B, participants will be required to alternately connect numbers (1-13) and letters (A-L) in sequence (E.G., 1-A, 2-B, 3-C, etc.) as quickly and accurately as possible. For both parts, completion time, the difference between Part B and Part A (B-A), the B/A ratio, and the number of errors will be recorded.

    Time frame: Baseline and 8 weeks

  4. Stroop Color and Word Test

    The test will be administered in three conditions: Stroop Part 1 (Word Reading), Stroop Part 2 (Color Naming), and Stroop Part 3 (Incongruent Word-Color Condition). In Part 1, participants will be presented with a list of color words and asked to read the words aloud. In Part 2, participants will be shown colored squares and asked to name the colors. In Part 3, participants will be presented with color words printed in incongruent ink colors and asked to name the ink color rather than reading the word. For all three parts, completion time, number of correct responses, and number of incorrect responses will be recorded.

    Time frame: Baseline and 8 weeks

  5. Dual-Task Gait Test

    The test will be administered under three conditions: cognitive dual-task, motor dual-task, and mixed dual-task. Participants will perform the test while walking on a flat, firm, and non-slip surface. Initially, participants will be asked to walk at a normal pace. Subsequently, dual-task conditions will be introduced, requiring participants to perform an additional task while walking. In the cognitive dual-task condition, a cognitive task will be added during walking. In the motor dual-task condition, an additional motor task will be performed while walking. In the mixed dual-task condition, an additional task will be performed during turning while walking. Test duration (Seconds) will be recorded using a stopwatch. Dual-Task Cost (DTC) will be calculated using the following formula: DTC (%) = \[(single-task performance - dual-task performance) / single-task performance\] × 100.

    Time frame: Baseline and 8 weeks

  6. Dual-Task Timed Up and Go (TUG) Test

    The test will be administered under three conditions: cognitive dual-task TUG, motor dual-task TUG, and mixed dual-task TUG. Participants will perform the test while seated on a standard chair placed on a flat, firm, and non-slip surface. In the standard condition, participants will be instructed to stand up from a chair, walk a set distance, turn around, walk back, and sit down again. Subsequently, dual-task conditions will be applied by adding an additional task during the TUG procedure. In the cognitive dual-task TUG, a cognitive task will be added during the test. In the motor dual-task TUG, an additional motor task will be included. In the mixed dual-task TUG, both cognitive and motor tasks will be performed simultaneously or task difficulty will be increased.Test completion time (Seconds) will be recorded using a stopwatch. Dual-Task Cost (DTC) will be calculated using the following formula: DTC (%) = \[(single-task performance - dual-task performance) / single-task perform

    Time frame: Baseline and 8 weeks

  7. Ruler Drop Test

    The test will be administered under three conditions: simple, selective, and dual-task. Participants will be seated with the forearm supported on a table and the elbow flexed at 90 degrees. In the simple condition, participants will be instructed to catch a falling ruler as quickly as possible when it is released. In the selective condition, participants will be required to catch the ruler only when a specific stimulus is presented. In the dual-task condition, participants will perform an additional task simultaneously while attempting to catch the ruler. The distance between the point of ruler release and the point of catch will be recorded. A total of three trials will be performed, and both the best and mean values will be recorded.

    Time frame: Baseline and 8 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 11 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07678983
Lead sponsor
Izmir Bakircay University
Responsible party
Gülbin Ergin (Prof.Dr, Izmir Bakircay University) — Principal investigator
First posted
Jul 1, 2026
Start date
Jan 20, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Gülbin Ergin, Prof. Dr
principal investigator · Izmir Bakircay University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion